Tirosina quinasa / adaptadores
Los inhibidores de tirosina quinasa y adaptadores son compuestos que se dirigen a las tirosina quinasas y sus proteínas adaptadoras asociadas, las cuales desempeñan roles cruciales en la señalización celular, el crecimiento y la diferenciación. Estos inhibidores son herramientas esenciales en la investigación del cáncer, ya que muchas tirosina quinasas están involucradas en las vías de señalización que impulsan el crecimiento tumoral y la metástasis. Al inhibir las tirosina quinasas, estos compuestos pueden bloquear cascadas de señalización críticas, ofreciendo potenciales estrategias terapéuticas para varios tipos de cáncer y otras enfermedades que implican una señalización celular anormal. En CymitQuimica, ofrecemos una amplia gama de inhibidores de tirosina quinasa y adaptadores de alta calidad para apoyar su investigación en oncología, biología molecular y desarrollo de terapias dirigidas.
Subcategorías de "Tirosina quinasa / adaptadores"
- ALK(114 productos)
- CSF-1R(42 productos)
- EGFR(572 productos)
- Receptor de efrina(23 productos)
- FLT(91 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(169 productos)
- HER(5 productos)
- Hck(3 productos)
- IGF-1R(91 productos)
- PDGFR(126 productos)
- PYK2(7 productos)
- Src(80 productos)
- Receptor TAM(32 productos)
- Tie-2(21 productos)
- Receptor de Trk(59 productos)
- Tirosina quinasas(26 productos)
- VEGFR(267 productos)
- c-Fms(108 productos)
- c-Kit(102 productos)
- c-Met / HGFR(129 productos)
- c-RET(51 productos)
Mostrar 13 subcategorías más
Se han encontrado 1357 productos de "Tirosina quinasa / adaptadores"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
JNJ-64264681
CAS:<p>JNJ-64264681 is a potent, orally active, selective, and irreversible covalent inhibitor of Bruton's tyrosine kinase (BTK).</p>Fórmula:C27H30N6O3SPureza:98%Forma y color:SolidPeso molecular:518.63FN-1501
CAS:<p>FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively).</p>Fórmula:C22H25N9OPureza:97.4%Forma y color:SolidPeso molecular:431.49EGFR-IN-73
CAS:<p>EGFR-IN-73 (Compound 3f) effectively inhibits the prevalent EGFR mutation, EGFR Del19, exhibiting an IC50 value of 119 nM [1].</p>Fórmula:C19H17ClFN3O4Pureza:98%Forma y color:SolidPeso molecular:405.81CGP52411
CAS:<p>CGP52411 is an orally active, and ATP-competitive inhibitor of EGFR (IC50: 0.3 μM).</p>Fórmula:C20H15N3O2Pureza:99.78%Forma y color:SolidPeso molecular:329.35Nazartinib mesylate
CAS:<p>Nazartinib mesylate is a novel, covalent mutant-selective inhibitor of EGFR (Ki and Kinact: 31 nM and 0.222/min on EGFR(L858R/790M) mutant).</p>Fórmula:C27H35ClN6O5SPureza:98%Forma y color:SolidPeso molecular:591.12ER-27319
CAS:<p>ER-27319, an acridone derivative, serves as a potent and selective inhibitor of spleen tyrosine kinase (SYK), effectively impeding both the tyrosine</p>Fórmula:C20H22N2O5Pureza:98%Forma y color:SolidPeso molecular:370.4RO9021
CAS:<p>RO9021 is an orally bioavailable, novel ATP-competitive SYK inhibitor (average IC50: 5.6 nM).</p>Fórmula:C18H25N7OPureza:97.19%Forma y color:SolidPeso molecular:355.44OXSI-2
CAS:<p>OXSI-2 (Syk Inhibitor) is an inhibitor of Syk with an EC50 of 313 nM and an IC50 of 14 nM.</p>Fórmula:C18H15N3O3SPureza:98%Forma y color:Dark Orange SolidPeso molecular:353.39EML4-ALK kinase inhibitor 1
CAS:<p>Potent oral EML4-ALK inhibitor with a 1 nM IC50.</p>Fórmula:C31H48N8O3Pureza:99.62%Forma y color:SolidPeso molecular:580.76CGP60474
CAS:<p>CGP60474 is an inhibitor of VEGFR-2 (IC50 = 84 nM) and an inhibitor of ATP-competitive PKC.</p>Fórmula:C18H18ClN5OPureza:98.81%Forma y color:SolidPeso molecular:355.82DMH4
CAS:<p>DMH4 is a potent and selective inhibitor of VEGFR2 with an IC50 of 0.16 µM.</p>Fórmula:C24H24N4O2Pureza:99.58%Forma y color:SolidPeso molecular:400.47AXL-IN-13
CAS:<p>AXL-IN-13: potent, oral AXL inhibitor, IC50=1.6nM, Kd=0.26nM, anti-cancer, inhibits EMT, cell migration & invasion.</p>Fórmula:C34H41FN6O5Pureza:99.20%Forma y color:SolidPeso molecular:632.72SDZ281-977
CAS:<p>SDZ 281-977 is a derivative of Lavendustin A which is the EGF receptor tyrosine kinase inhibitor.</p>Fórmula:C18H20O5Pureza:99.64%Forma y color:SolidPeso molecular:316.35RTC-5
CAS:<p>RTC-5 (TRC-382) is a phenothiazine compound that has been specifically enhanced for its potent anti-cancer properties.</p>Fórmula:C24H22ClF3N2O3SPureza:98.14%Forma y color:SolidPeso molecular:510.96c-Kit-IN-2
CAS:c-Kit-IN-2 is a c-KIT inhibitor (IC50: 82 nM), shows superior antiproliferative activities against all the three GIST cell lines, GIST430, GIST882, and GIST48 (Fórmula:C25H29N9O2SPureza:98%Forma y color:SolidPeso molecular:519.62EGFR-IN-16
CAS:<p>EGFR-IN-16 (AG473) is an inhibitor of EGFR in human A431 cells.</p>Fórmula:C16H11NO3Pureza:98%Forma y color:SolidPeso molecular:265.26Epertinib
CAS:<p>Epertinib is a reversible and selective tyrosine kinase inhibitor of EGFR, HER2, and HER4 (IC50s: 1.48 nM, 7.15 nM, and 2.49 nM).</p>Fórmula:C30H27ClFN5O3Pureza:98%Forma y color:SolidPeso molecular:560.02Tarlox-TKI
CAS:Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, which has antitumor activity.Fórmula:C19H18BrClN6OPureza:97.03%Forma y color:SolidPeso molecular:461.74Glesatinib
CAS:Glesatinib is an orally active and potent dual inhibitor of MET/SMO.Fórmula:C31H27F2N5O3S2Pureza:98%Forma y color:SolidPeso molecular:619.7FLT3-IN-4
CAS:<p>FLT3-IN-4 (FLT3 inhibitor 9u) is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC50=7 nM) inhibitor ,for treating acute myelogenous</p>Fórmula:C23H25N7O2Pureza:99.9%Forma y color:SolidPeso molecular:431.49Nimotuzumab
CAS:<p>Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).</p>Pureza:95.00% - 98.5% (SDS-PAGE); 96.4% (SEC-HPLC)Forma y color:LiquidEGFR-IN-21
CAS:<p>EGFR-IN-21, a potent EGFR inhibitor, exhibits an IC50 of 0.38 nM, demonstrating significant antitumor activity.</p>Fórmula:C36H44BrN10O2PForma y color:SolidPeso molecular:759.68EGFR-IN-55
CAS:<p>"EGFR-IN-55 targets EGFRWT (70 nM IC50) & EGFRL858R/T790M (3.9 nM IC50), halts NCI-H1975 cell cycle in G0/G1, showing anticancer properties."</p>Fórmula:C25H25Cl2N7O2Forma y color:SolidPeso molecular:526.42IACS-9439
CAS:<p>IACS-9439 is a potent, selective, and orally active inhibitor of CSF1R, exhibiting a K(i) of 1 nM.</p>Fórmula:C23H26ClN7O3SPureza:98%Forma y color:SolidPeso molecular:516.02EGFR-IN-49
CAS:<p>EGFR-IN-49 selectively inhibits EGFR mutations T790M (IC50: 65 nM) & T790M/L858R (IC50: 13.6 nM), triggering apoptosis dose-dependently.</p>Fórmula:C22H15N5O2SForma y color:SolidPeso molecular:413.45MMPP
CAS:<p>MMPP is a VEGFR2 inhibitor with anti-inflammatory activity, inhibits STAT3 , inhibits angiogenesis, and can be used to alleviate myocardial injury.</p>Fórmula:C17H18O3Pureza:99.31% - 99.83%Forma y color:SolidPeso molecular:270.32Sotuletinib dihydrochloride
CAS:<p>Sotuletinib (BLZ945) dihydrochloride is an orally administered, blood-brain barrier-permeable inhibitor specifically targeting CSF1-R with an IC50 of 1 nM.</p>Fórmula:C20H24Cl2N4O3SPureza:98%Forma y color:SolidPeso molecular:471.4Syk-IN-3
CAS:<p>Syk-IN-3 is a Syk inhibitor with potential anti-inflammatory and anticancer activity and can be used to study immune dysregulation.</p>Fórmula:C24H28N4O3SPureza:97.29% - >99.99%Forma y color:SolidPeso molecular:452.57PDZ1i
CAS:<p>PDZ1i: potent MDA-9/Syntenin inhibitor; crosses blood-brain barrier; targets GBM, FAK, EGFRvIII; lowers MMP secretion.</p>Fórmula:C28H26N8O4Forma y color:SolidPeso molecular:538.56BIBX 1382 Dihydrochloride
CAS:<p>BIBX 1382 Dihydrochloride blocks Lassa/Ebola entry, aids in studying virus-host interactions, and hints at kinase targets for therapy.</p>Fórmula:C18H21Cl3FN7Forma y color:SolidPeso molecular:460.76EGFR-IN-31
CAS:<p>EGFR-IN-31: Potent EGFR inhibitor, targets mutations & overexpression in NSCLC; potential cancer research compound. (WO2021185298A1, 2)</p>Fórmula:C32H36FN7O2Forma y color:SolidPeso molecular:569.67c-Fms-IN-8
CAS:c-Fms-IN-8 is a colony-stimulating factor-1 receptor (CSF-1R, c-FMS) Type II inhibitor (IC50: 9.1 nM). It is compound 4a in the reference.Fórmula:C27H30N2O5Pureza:98%Forma y color:SolidPeso molecular:462.54LDC0496
CAS:<p>LDC0496: Potent EGFR/Her2 exon 20 inhibitor; selective for wild-type EGFR, kinase-specific.</p>Fórmula:C32H35N5O3Forma y color:SolidPeso molecular:537.65EGFR-IN-69
CAS:<p>EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.</p>Fórmula:C31H37Cl2N7O3SForma y color:SolidPeso molecular:658.64c-Fms-IN-9
CAS:c-Fms-IN-9 inhibits c-FMS/uFMS and uKIT with IC50 <0.01μM and 0.1-1μM, from patent WO2014145023A1.Fórmula:C21H23N7O2Pureza:98%Forma y color:SolidPeso molecular:405.45NSC114126
CAS:<p>NSC114126 is a potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Fórmula:C22H20O4Forma y color:SolidPeso molecular:348.39Selatinib
CAS:<p>Selatinib is an orally active and potent dual inhibitor of EGFR and ErbB2 with anticancer activity that inhibits the growth of NCI-N87 tumor cells.</p>Fórmula:C29H26ClFN4O3SPureza:98.00%Forma y color:SolidPeso molecular:565.06EGFR-IN-50
CAS:<p>EGFR-IN-50, a potent EGFR blocker, hinders L858R mutation; GI50: 8 nM for TEL-EGFR-L858R, 6.03 μM for T790M-L858R; curbs cancer cell growth.</p>Fórmula:C24H26BrN3O4S2Forma y color:SolidPeso molecular:564.51Glesatinib hydrochloride
CAS:<p>Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO.</p>Fórmula:C31H28ClF2N5O3S2Pureza:98%Forma y color:SolidPeso molecular:656.16AG-183
CAS:<p>(Z)-Tyrphostin A51, a Z-isomer of Lanoconazole A51, is a strong PTK inhibitor blocking [3 H]taurine release and tyrosyl phosphorylation.</p>Fórmula:C13H8N4O3Forma y color:Brown SolidPeso molecular:268.23c-Kit-IN-3
CAS:<p>c-Kit-IN-3 is a selective inhibitor of c-KIT kinase with IC50s of 4 nM and 8 nM for c-Kit (wt) and c-Kit (T670I).</p>Fórmula:C26H20ClF3N2O4Pureza:99.94%Forma y color:SolidPeso molecular:516.9NSC81111
CAS:<p>NSC81111 shows anticaner effects which is a potent and orally active inhibitor of EGFR-TK (IC50 = 0.15 nM) [1].</p>Fórmula:C19H16O4Forma y color:SolidPeso molecular:308.33Ansornitinib
CAS:<p>Ansornitinib (ANG-3070) is a KDR and PDGF receptor inhibitor with antifibrotic activity for the study of diseases caused by abnormal or excessive fibrosis.</p>Fórmula:C30H32N6O4Forma y color:SolidPeso molecular:540.61FGFR2-IN-1
CAS:<p>FGFR2-IN-1 is an FGFR inhibitor that inhibits FGFR1, FGFR2, and FGFR3, and can be used to study FGFR2-associated cancers.</p>Fórmula:C22H19N3O2Pureza:98.71%Forma y color:SolidPeso molecular:357.41GW 583340 dihydrochloride
CAS:<p>GW 583340 dihydrochloride is a potent and orally available dual EGFR/ErbB2 inhibitor and inhibits 80% of tumor growth in a mouse xenograft mode.</p>Fórmula:C28H27Cl3FN5O3S2Pureza:98.80%Forma y color:SolidPeso molecular:671.03CE-245677 mesylate
CAS:<p>CE-245677 mesylate is a selective Tie2 kinase inhibitor with oral activity and potential anti-tumor effects, useful in pain research.</p>Fórmula:C25H26Cl2N6O6SPureza:99.42%Forma y color:SolidPeso molecular:609.48c-Fms-IN-1
CAS:<p>c-Fms-IN-1 is an inhibitor of c-FMS kinase (IC50 = 0.8 nM).</p>Fórmula:C22H27N5O2Pureza:99.94%Forma y color:SolidPeso molecular:393.48EGFR-IN-67
CAS:<p>EGFR-IN-67 (Compound 7d) is a potent inhibitor of EGFR with anticancer activity (IC 50 = 0.34 μM) [1].</p>Fórmula:C18H17N3SForma y color:SolidPeso molecular:307.41Mutated EGFR-IN-3
CAS:<p>Mutated EGFR-IN-3: ATP-competitive, selective dibenzodiazepinone inhibitor for EGFR mutations, IC50 12-13 nM.</p>Fórmula:C31H29FN4O2Pureza:98%Forma y color:SolidPeso molecular:508.59MS 154N
CAS:<p>MS 154N is a negative control for MS 154, binds WT/L858R EGFR tightly (Kd 3-4.3nM), doesn't trigger mutant EGFR degradation.</p>Fórmula:C47H56ClFN8O8Forma y color:SolidPeso molecular:915.45
